Home›Allergy & Immunology› Meningeal Immune System Offers New Target for Glioblastoma Immunotherapy
Meningeal Immune System Offers New Target for Glioblastoma ImmunotherapyNew approach targets the immune system to treat brain tumors
Frontiers in MedicinePublished June 15, 2026DOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Targeting the meningeal immune system may overcome current barriers in glioblastoma immunotherapy by focusing on the tumor border.
Glioblastoma (GBM) remains one of the most challenging cancers to treat, with immunotherapy showing limited success due to the tumor's immunosuppressive microenvironment and the blood-brain barrier. This systematic review examines the emerging role of the meningeal immune system as a potential new frontier for GBM immunotherapy.
The meninges, long considered merely protective layers, are now recognized as active immune hubs. The review details the anatomical and functional basis of meningeal immunity, including the dural lymphatic system and recently discovered border-associated macrophages (rBAMs). These components form a specialized immune surveillance network that interfaces with the central nervous system.
A key insight is the concept of interstitial immunotherapy—shifting therapeutic focus from the tumor core to the tumor border, where active immune interactions occur. By leveraging the meningeal immune system, novel strategies could enhance antigen presentation, T-cell priming, and immune cell trafficking to the tumor site.
The review discusses theoretical implications and clinical translation prospects, though it acknowledges that direct clinical evidence is still lacking. It provides a framework for future research, emphasizing the need to understand how GBM hijacks meningeal immunity and how to therapeutically redirect it.
Overall, this work offers a compelling rationale for exploring meningeal-targeted immunotherapies, potentially opening new avenues for treating this devastating disease.
How this fits prior evidence
This systematic review extends prior coverage by proposing a novel therapeutic focus on the meningeal immune system and interstitial immunotherapy for glioblastoma, which contrasts with earlier work on TOX/TCF-1 axis dysregulation and IDH-driven silencing as mechanisms of cytotoxic failure. It also complements the meta-analysis linking high platelet ratios to worse survival by suggesting an alternative immune-based approach. The review does not directly address tumor treating fields or glioma organoid models, but its emphasis on the tumor border aligns with the concept of local therapy delivery.
Living with a glioblastoma diagnosis means facing one of the toughest challenges in cancer care. Current treatments often struggle to reach the tumor effectively. This review looks at a different path: focusing on the meningeal immune system, which is the layer of tissue and fluid surrounding the brain.
By targeting this specific area, researchers hope to improve how immunotherapy works. The study highlights the importance of the dural lymphatic system and specialized cells called rBAMs. These parts of the body act as a gateway for the immune system to interact with the tumor border.
It is important to note that this review looks at existing research rather than new clinical trials. While it provides a strong theoretical map for future treatments, there are no specific trial results or patient data yet. It offers a promising framework for how doctors might design better ways to fight these tumors in the future.
What this means for you:
Targeting the immune system at the tumor border could offer a new way to treat glioblastoma.
Common questions
What is interstitial immunotherapy?
Interstitial immunotherapy is a strategy that shifts the focus of treatment toward the border where a tumor meets the body's immune system. By targeting this specific area, researchers hope to improve how treatments work for glioblastoma.
What is the meningeal immune system?
The meningeal immune system includes the anatomical and functional parts of the brain's outer layers. This includes the dural lymphatic system and specialized cells called rBAMs, which help manage the body's immune response near the brain.
Is this a new treatment for glioblastoma?
This is not a new drug or a completed clinical trial. It is a review of existing research that provides theoretical support and practical guidance for how future treatments might be designed to target the tumor border.
Glioblastoma (GBM) is one of the most aggressive brain tumors, and its immunotherapy faces significant challenges, including the physical barrier of the blood-brain barrier, the tumor immunosuppressive microenvironment, and the difficulty of effective immune cell infiltration into tumor tissue. In recent years, the anatomical and functional basis of the meningeal immune system has been gradually revealed, particularly the discovery of the dural lymphatic system and tissue-resident border-associated macrophages (rBAMs), providing new insights for GBM immunotherapy. “Interstitial” immunotherapy, as an innovative strategy, emphasizes a shift from the traditional focus on the tumor interior to the tumor “border,” leveraging the unique advantages of the meningeal immune system to enhance the effectiveness of immune responses. This review systematically examines the current status and dilemmas of GBM immunotherapy, the anatomical and functional basis of meningeal immunity, the discovery and mechanisms of rBAMs, the theoretical implications of “interstitial” immunotherapy, and the clinical translation prospects and challenges of this strategy, aiming to provide new theoretical support and practical guidance for GBM immunotherapy.
